Vitamin D deficiency remains the most common cause of Osteomalacia & rickets.
My first presentation prepared by me as a first year family medicine board resident. đ
INTRODUCTION â Normal bone growth and mineralization require adequate calcium and phosphate, the two major constituents of the crystalline component of bone. Deficient mineralization can result in rickets and/or osteomalacia. Rickets refers to deficient mineralization at the growth plate, as well as architectural disruption of this structure. Osteomalacia refers to impaired mineralization of the bone matrix. Rickets and osteomalacia usually occur together as long as the growth plates are open; only osteomalacia occurs after the growth plates have fused.
rickets is a nutritional deficiency disease that involves mainly calcium, vitamin d, or phosphate resulting in decreased bone stability and strength, Delayed closure of the fontanelles,Parietal and frontal bossing. Craniotabes (soft skull bones).
Enlargement of the costochondral junction visible as beading along the anterolateral aspects of the chest (the "rachitic rosary") . Formation of Harrison sulcus (or groove),Widening of the wrist and bowing of the distal radius and ulna, Progressive lateral bowing of the femur and tibia and causes defects in teeth.
there is two types of rickets: phosphopenic and calcipenic.
pathogenesis: Growth plate thickness is determined by two opposing processes: o chondrocyte proliferation and hypertrophy on the one hand. o vascular invasion of the growth plate followed by conversion into primary bone spongiosa on the other. ⢠Vascular invasion requires mineralization of the growth plate cartilage and is delayed or prevented by deficiency of calcium or phosphorus ď growth plate cartilage accumulates and the growth plate thickens. ⢠In addition, the chondrocytes of the growth plate become disorganized, losing their columnar orientation with characteristic expansion of the hypertrophic zone. ⢠In the bone tissue below the growth plate (metaphysis), the mineralization defect leads to the accumulation of osteoid.
INTRODUCTION â Normal bone growth and mineralization require adequate calcium and phosphate, the two major constituents of the crystalline component of bone. Deficient mineralization can result in rickets and/or osteomalacia. Rickets refers to deficient mineralization at the growth plate, as well as architectural disruption of this structure. Osteomalacia refers to impaired mineralization of the bone matrix. Rickets and osteomalacia usually occur together as long as the growth plates are open; only osteomalacia occurs after the growth plates have fused.
rickets is a nutritional deficiency disease that involves mainly calcium, vitamin d, or phosphate resulting in decreased bone stability and strength, Delayed closure of the fontanelles,Parietal and frontal bossing. Craniotabes (soft skull bones).
Enlargement of the costochondral junction visible as beading along the anterolateral aspects of the chest (the "rachitic rosary") . Formation of Harrison sulcus (or groove),Widening of the wrist and bowing of the distal radius and ulna, Progressive lateral bowing of the femur and tibia and causes defects in teeth.
there is two types of rickets: phosphopenic and calcipenic.
pathogenesis: Growth plate thickness is determined by two opposing processes: o chondrocyte proliferation and hypertrophy on the one hand. o vascular invasion of the growth plate followed by conversion into primary bone spongiosa on the other. ⢠Vascular invasion requires mineralization of the growth plate cartilage and is delayed or prevented by deficiency of calcium or phosphorus ď growth plate cartilage accumulates and the growth plate thickens. ⢠In addition, the chondrocytes of the growth plate become disorganized, losing their columnar orientation with characteristic expansion of the hypertrophic zone. ⢠In the bone tissue below the growth plate (metaphysis), the mineralization defect leads to the accumulation of osteoid.
Osteoporosis is a chronic, progressive disease of multifactorial etiology.
It is most frequently recognized in particularly in elderly people and does occur in sexes, all races, and all age groups.
Osteoporosis is a preventable disease that can result in disturbing physical, psychosocial, and economic consequences.
Osteoporosis is a systemic skeletal disease characterized by low bone mass and micro architectural deterioration of bone tissue.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Â
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowmanâs Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Â
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Â
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? â The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
Â
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Â
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganongâs Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Prix Galien International 2024 Forum ProgramLevi Shapiro
Â
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMENâS HEALTH: FERTILITY PRESERVATION
- WHATâS NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
Â
RESULTS: Overall life span (LS) was 2252.1Âą1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years â 64.8%, 20 years â 42.5%. 513 LCP lived more than 5 years (LS=3124.6Âą1525.6 days), 148 LCP â more than 10 years (LS=5054.4Âą1504.1 days).199 LCP died because of LC (LS=562.7Âą374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0âN12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0âN12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
Â
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
NVBDCP.pptx Nation vector borne disease control program
Â
Osteomalacia & Rickets
1. Osteomalacia and
Rickets
Family Medicine Residency Program
Supervised by: Assistant Prof. D.Ali Shakir, Dr.Lara Abbas
Prepared by: Dr.Shajwan Hdayat Dara
27 Mar.2023
2. Introduction:
⢠Osteomalacia is a disorder of deficient mineralization of newly formed
osteoid at sites of bone turnover and manifestations are more subtle
& frequently overlooked.
⢠Rickets is a disorder of defective mineralization of both cartilaginous
growth plate & bone causing characteristic deformities.
⢠Both can occur together in children (open growth plate), but only
Osteomalacia occurs in adults (fused growth plate).
3. Pathophysiology:
⢠Normal bone mineralization :
1. Availability of sufficient Ca & phosphorus.
2. Presence of normal bone collagen.
3. Absence of inhibitors of mineralization.
4. Adequate amount of alkaline phosphatase activity.
*any defect in these requirements are the cause of most forms of Osteomalacia &
rickets.
9. Epidemiology:
⢠Nutritional Rickets continues to be an evolving & multifactorial
problem worldwide.
⢠About 25% of women in US have 25-OHD level <25 ng/ml & 8% below
12 ng/ml.
⢠Osteomalacia & rickets must be excluded before administration of
antiresorptive drugs used for postmenopausal osteoporosis.
⢠Recent migration to Europe & US has been accompanied by
resurgence of deficiency diseases especially vit D def.
*Goldman-Cecil medicine textbook, 26th ed.
10. Clinical manifestations of Osteomalacia:
⢠Depending of extent of mineralization delay, overt Osteomalacia may take
many years to develop.
⢠Symptoms may be insidious in onset & present radiologically as osteopenia.
⢠Most common Sx: pelvis & leg pain, muscle weakness & bone tenderness.
⢠The pain is dull, poorly localized aggreviated by sudden movements & weight
bearing resulting in a âwaddling gaitâ made worse by proximal muscle
weakness.
⢠Patients may complain that they can only climb stairs by pulling themselves up
with hand rail or rise from a chair or toilet by using their hands to push off.
⢠So decrease in strength is far greater than muscle wasting.
11. Clinical manifestations cont.
⢠Fracture with little or no trauma (ribs, vertebrae & long bones).
⢠Paresthesias, muscle cramp, seizurs & +ve Chvostekâs sign (severe hypocalcemia).
⢠Spinal, thoracic & pelvic deformity (severe long standing Osteomalacia)
⢠In XLH: +ve FH, short stature & lower leg deformity.
12. Clinical manifestations of Rickets:
⢠Most common during first 2 yr of life & may become evident only after several
months of a vit D-deficient diet.
⢠Skeletal findings Initially manifest at distal forearm, knees & costochondral
junctions (sites of rapid bone growth with greatest demand for Ca & P).
⢠Extraskeletal findings: dental hypoplasia in calcipenic rickets, dental abscesses
in hereditary phosphopenic rickets.
13.
14. Radiographic findings:
⢠Radiological abnormalities in Osteomalacia are
less striking than in rickets & may be subtle or
absent.
⢠Presence of bilaterally symmetrical, thin (2-
3mm) radiolucent bands known as
pseudofractures found perpendicular to
cortical margins of ribs, pubic & ischial rami,
neck of femur, metatarsals & scapulae is
generally considered to be pathognomonic of
Osteomalacia.
19. Diagnosis of Osteomalacia:
⢠A delay in diagnosis is commonly reported because clinicians consider
other differentials prior to confirmation of Osteomalacia including
OA, osteoporosis, paget disease, CA, malabsorption, IBS, depression..
⢠History: it should be suspected in cases of bone pain associated with
GI malabsorption, CKD or Chronic liver disease. Onset, dietary habits,
sun exposure, surgical procedures, drug hx.
⢠Radiologic findings: to distinguish Osteomalacia from multiple
myeloma or paget disease.
20. Diagnosis of Osteomalacia cont:
⢠Histomorphometric assessment:
⢠transiliac crest bone biopsy using double tetracycline labelling is most
accurate way to dx Osteomalacia. However itâs infrequently
performed clinically because itâs invasive & dx can usually be made
from combination of clinical, lab & radiologic findings.
⢠indicated when in doubt or the cause is not determined by
noninvasive testing eg. Rare disorders as axial Osteomalacia or
fibrogenesis imperfecta.
21. Diagnosis of Osteomalacia cont:
⢠Bone Mineral Density:
⢠several studies have shown markedly reduced spine, hip & forearm
BMD as measured by DEXA in pt with vit-D deficient Osteomalacia.
⢠However, BMD is not required for Dx of ostemalacia & unable to
differentiate it from osteoporosis.
28. Treatment & prognosis:
⢠Rx is directed at reversal of underlying disorder & correction of
mineral deficiencies. Response to appropriate Rx is usually excellent.
⢠Improvements in bone pain & muscle weakness usually occur within
2-3 mo & healing of skeletal lesions within 6-18 mo.
⢠Bone density improvement from Rx may continue for up to a year.
⢠Depending on the quantity of excess osteoid, repeat BMD may show
as much as 20% gains at lumbar spine & total proximal femur.
29. Treatment & prognosis cont:
⢠However, BMD at radial diaphysis may not improve due to irreversible
loss of cortical bone resulting from prolonged secondary
hyperparathyroidism.
⢠Presence of decreased bone volume in addition to excess osteoid,
skeletal recovery may be incomplete resulting in residual osteoporosis.
⢠However, caution must be considered before adding antiresorptive agent
& wait for normalization of Ca, Pi & alkaline phosphatase.
30.
31.
32.
33. Treatment of Vit-D deficiency in Rickets:
â˘Daily therapy â The most widely used Rx consists of daily replacement
doses of vitD2 or vitD3. The following dosing is recommended for children
without underlying defects in intestinal absorptive function:
⢠â˘Infants <1 mo â 1000 IU daily for up to three months, followed by
maintenance dosing of 400 IU daily.
⢠â˘Infants 1 to 12 mo â 1000 to 2000 IU daily for up to three months, followed by
maintenance dosing of 400 IU daily.
⢠â˘Children 1 to 12 yr â 2000 to 6000 IU daily for three months, followed by
maintenance dosing of 600 IU daily.
⢠â˘Children âĽ12 yr â 6000 IU daily for three months, followed by maintenance
dosing of 600 IU daily.
34. Treatment of Vit-D deficiency in Rickets:
â˘Stoss therapy â An alternative Rx protocol which consists of a
high dose of vitamin D given on a single day. The Global Consensus
prefers daily therapy rather than stoss therapy, but recognizes that it is
sometimes more practical & provides the following dosing using
oral vitamin D3 & not vitD2:
⢠â˘Infants <3 moâ Stoss therapy not recommended
⢠â˘Infants 3 to 12 moâ A single dose of 50,000 IU
⢠â˘Children 1 to 12 yr â A single dose of 150,000 IU
⢠â˘Children ⼠12 yr â A single dose of 300,000 IU
35. Monitoring of VitD Therapy:
Serum Ca, Pi, alkaline phosphatase & urinary Ca:cr ratio should be measured 4
weeks after the start of therapy.
⢠They become normalized except urinary Ca:Cr ratio may still be low.
⢠These tests should be repeated monthly until doses are adjusted downward to
a typical daily replacement amount.
⢠This typically occurs by three months of therapy, at which time radiographs can
be obtained to document the healing of rachitic lesions.
⢠Monitoring is also important to ensure that no toxicity has occurred.
36. Treatment of calcium deficiency rickets:
⢠It can be treated by ensuring a daily intake of 1000 mg of calcium and
maintenance of vitamin D intake at the recommended daily value.
37. Prevention:
⢠High risk populations (eg. Dark skinned, immigrants) require lifelong
supplementation & food fortification with vitD or Ca.
⢠Optimal vitD supplementation isnât clear but most bone & mineral problems are
avoided by 50,000 IU cholecalciferol given once monthly. Except in pt with celiac
disease, gastric operation or bypass for obesity who often require much larger
amounts.
⢠VitD is recommended for all breast-fed infants as 400 IU/d started soon after
birth& given until the infant is taking >1000 IU of formula or vitD-fortified milk
(for age>1 yr).